Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728752 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
A Phase 3 study of Dermatomyositis, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT02728752 is a Phase 3 study of Dermatomyositis that has completed, run by Octapharma. The registered enrollment target is 95 participants, below the 480-participant average among 19 other Dermatomyositis trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02728752, a Phase 3 study of Dermatomyositis, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM study")
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Octagam 10%
Study Locations (20)
Florida
- Octapharma Research Site - Orlando
- NeuroMedical Research Center - Panama City
- Octapharma Research Site - Plantation
- University of South Florida - Tampa
California
- Octapharma Research Site - Huntington Beach
- Octapharma Research Site - Los Angeles
- University of California -Irvine - Orange
Texas
- Austin Neuromuscular Center - Austin
- Octapharma Research Site - Houston
- Arthritis & Osteoporosis Clinic - Waco
Other
- Revmatologický ústav - Prague
- Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie - Berlin
Kansas
- Octapharma Research Site - Kansas City
Michigan
- Octapharma Research Site - Ann Arbor
Minnesota
- Octapharma Research Site - Rochester
New York
- Octapharma Research Site - Great Neck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2019-11-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728752
The ClinicalTrials.gov registry entry for NCT02728752 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 480-participant average among 19 other Dermatomyositis trials with a reported enrollment target (80% lower). The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatomyositis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02728752 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT02728752 about?
NCT02728752 is a clinical study titled "Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)". Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM study")
What is the current status of trial NCT02728752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2017-02-27. Estimated completion is 2019-11-05.
What conditions does trial NCT02728752 study?
This clinical trial studies the following conditions: Dermatomyositis.
What interventions are being tested in trial NCT02728752?
The interventions under investigation include: Placebo (OTHER), Octagam 10% (DRUG).
Who is sponsoring clinical trial NCT02728752?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02728752 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 3
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
RECRUITING
-
Adult and Juvenile Myositis
RECRUITING
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.